Literature DB >> 16125825

Extraordinarily few organisms of a live recombinant BCG vaccine against tuberculosis induce maximal cell-mediated and protective immunity.

Marcus A Horwitz1, Günter Harth, Barbara Jane Dillon, Sasa Maslesa-Galić.   

Abstract

In previous studies, we have described a live recombinant BCG vaccine (rBCG30) overexpressing the 30 kDa major secretory protein of Mycobacterium tuberculosis that induces greater protective immunity against tuberculosis than the current vaccine in the demanding guinea pig model of pulmonary tuberculosis. In this study, we have investigated the impact of vaccine dose on the development of cell-mediated and protective immunity in the guinea pig model. We found that the protective efficacy against M. tuberculosis aerosol challenge of both BCG and rBCG30 was essentially dose-independent over a dose range of 10(1)-10(6) live organisms. As previously observed, rBCG30 was more potent, reducing colony-forming units (CFU) below the level observed in animals immunized with the parental BCG vaccine by 0.7 logs in the lungs and 1.0 logs in the spleen (P<0.0001). To gain a better understanding of the influence of dose on bacterial clearance and immunity, we assessed animals immunized with 10(1), 10(3), or 10(6)CFU of rBCG30. The higher the dose, the higher the peak CFU level achieved in animal organs. However, whereas humoral immune responses to the 30 kDa protein reflected the disparate CFU levels, cell-mediated immune responses did not; high and low doses of rBCG30 ultimately induced comparable peak lymphocyte proliferative responses and cutaneous delayed-type hypersensitivity responses to the 30 kDa protein. We estimate that the amount of the 30 kDa protein required to induce a strong cell-mediated immune response when delivered via 10 rBCG30 organisms is about 9 orders of magnitude less than that required when the protein is delivered in a conventional protein/adjuvant vaccine. This study demonstrates that a very low inoculum of rBCG30 organisms has the capacity to induce strong protective immunity against tuberculosis and that rBCG30 is an extremely potent delivery system for mycobacterial antigens.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16125825     DOI: 10.1016/j.vaccine.2005.08.001

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

Review 1.  Recombinant BCGs for tuberculosis and bladder cancer.

Authors:  Alok K Singh; Geetha Srikrishna; Trinity J Bivalacqua; William R Bishai
Journal:  Vaccine       Date:  2021-09-27       Impact factor: 3.641

2.  Francisella tularensis Live Vaccine Strain deficient in capB and overexpressing the fusion protein of IglA, IglB, and IglC from the bfr promoter induces improved protection against F. tularensis respiratory challenge.

Authors:  Qingmei Jia; Richard Bowen; Bai-Yu Lee; Barbara Jane Dillon; Saša Masleša-Galić; Marcus A Horwitz
Journal:  Vaccine       Date:  2016-08-28       Impact factor: 3.641

3.  Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis.

Authors:  Hans-Willi Mittrücker; Ulrich Steinhoff; Anne Köhler; Marion Krause; Doris Lazar; Peggy Mex; Delia Miekley; Stefan H E Kaufmann
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-18       Impact factor: 11.205

4.  A Replication-Limited Recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG.

Authors:  Michael V Tullius; Günter Harth; Sasa Maslesa-Galic; Barbara J Dillon; Marcus A Horwitz
Journal:  Infect Immun       Date:  2008-08-25       Impact factor: 3.441

5.  Commonly administered BCG strains including an evolutionarily early strain and evolutionarily late strains of disparate genealogy induce comparable protective immunity against tuberculosis.

Authors:  Marcus A Horwitz; Günter Harth; Barbara Jane Dillon; Sasa Maslesa-Galić
Journal:  Vaccine       Date:  2008-11-11       Impact factor: 3.641

6.  Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy.

Authors:  Angela M Minassian; Edward O Ronan; Hazel Poyntz; Adrian V S Hill; Helen McShane
Journal:  PLoS One       Date:  2011-05-24       Impact factor: 3.240

7.  Cellular immune responses to nine Mycobacterium tuberculosis vaccine candidates following intranasal vaccination.

Authors:  Suraj B Sable; Mani Cheruvu; Subhadra Nandakumar; Sunita Sharma; Kakali Bandyopadhyay; Kathryn L Kellar; James E Posey; Bonnie B Plikaytis; Rama Rao Amara; Thomas M Shinnick
Journal:  PLoS One       Date:  2011-07-25       Impact factor: 3.240

Review 8.  A century of BCG vaccination: Immune mechanisms, animal models, non-traditional routes and implications for COVID-19.

Authors:  Shivani Singh; Noemi Alejandra Saavedra-Avila; Sangeeta Tiwari; Steven A Porcelli
Journal:  Front Immunol       Date:  2022-08-26       Impact factor: 8.786

9.  Immunogenicity and protective efficacy of a novel recombinant BCG strain overexpressing antigens Ag85A and Ag85B.

Authors:  Chun Wang; Ruiling Fu; Zhenhua Chen; Kun Tan; Lingxia Chen; Xindong Teng; Jia Lu; Chunwei Shi; Xionglin Fan
Journal:  Clin Dev Immunol       Date:  2012-04-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.